Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
Int J Geriatr Psychiatry 2008; 23(1):73-8IJ

Abstract

BACKGROUND

Donepezil is a drug used for treatment in patients with Alzheimer's disease (AD). Information regarding the cost-effectiveness of this medication was previously rare in Asia. We used techniques of decision analysis and economic evaluation in conjunction with available local epidemiological and clinical data on costs of mild to moderate AD to assess the cost-effectiveness of donepezil in Taiwan.

METHODS

A four-state Markov model was built to simulate the disease progression of AD patients. Local transition probabilities and costs of different stages were from the studies published earlier.

RESULTS

Over a 5-year span, donepezil treatment for mild or moderate AD patients is predicted to result in the gain of 0.505 QALYs when comparing to usual care, while at the same time reducing the cost by US$7,691. The incremental cost was US$3,647 from the payer perspective; thus, the incremental cost-effectiveness ratio was estimated to be US$7,226 when considering only the medical expenditures.

CONCLUSIONS

Under some assumptions, donepezil treatment might be a cost saving strategy for mild to moderate AD patients in Taiwan from a societal perspective. It is inconclusive from the payer's part since we still lack a consensus for judging the cost-effectiveness of a new health care technology.

Authors+Show Affiliations

Neurological Institute, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan. jlfuh@vghtpe.gov.twNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17520661

Citation

Fuh, Jong-Ling, and Shuu-Jiun Wang. "Cost-effectiveness Analysis of Donepezil for Mild to Moderate Alzheimer's Disease in Taiwan." International Journal of Geriatric Psychiatry, vol. 23, no. 1, 2008, pp. 73-8.
Fuh JL, Wang SJ. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan. Int J Geriatr Psychiatry. 2008;23(1):73-8.
Fuh, J. L., & Wang, S. J. (2008). Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan. International Journal of Geriatric Psychiatry, 23(1), pp. 73-8.
Fuh JL, Wang SJ. Cost-effectiveness Analysis of Donepezil for Mild to Moderate Alzheimer's Disease in Taiwan. Int J Geriatr Psychiatry. 2008;23(1):73-8. PubMed PMID: 17520661.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan. AU - Fuh,Jong-Ling, AU - Wang,Shuu-Jiun, PY - 2007/5/24/pubmed PY - 2008/5/13/medline PY - 2007/5/24/entrez SP - 73 EP - 8 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 23 IS - 1 N2 - BACKGROUND: Donepezil is a drug used for treatment in patients with Alzheimer's disease (AD). Information regarding the cost-effectiveness of this medication was previously rare in Asia. We used techniques of decision analysis and economic evaluation in conjunction with available local epidemiological and clinical data on costs of mild to moderate AD to assess the cost-effectiveness of donepezil in Taiwan. METHODS: A four-state Markov model was built to simulate the disease progression of AD patients. Local transition probabilities and costs of different stages were from the studies published earlier. RESULTS: Over a 5-year span, donepezil treatment for mild or moderate AD patients is predicted to result in the gain of 0.505 QALYs when comparing to usual care, while at the same time reducing the cost by US$7,691. The incremental cost was US$3,647 from the payer perspective; thus, the incremental cost-effectiveness ratio was estimated to be US$7,226 when considering only the medical expenditures. CONCLUSIONS: Under some assumptions, donepezil treatment might be a cost saving strategy for mild to moderate AD patients in Taiwan from a societal perspective. It is inconclusive from the payer's part since we still lack a consensus for judging the cost-effectiveness of a new health care technology. SN - 0885-6230 UR - https://www.unboundmedicine.com/medline/citation/17520661/Cost_effectiveness_analysis_of_donepezil_for_mild_to_moderate_Alzheimer's_disease_in_Taiwan_ L2 - https://doi.org/10.1002/gps.1842 DB - PRIME DP - Unbound Medicine ER -